Integrated assessment of PD-LI expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer

Purpose: Targeting the PD-1/PD-L1 pathway has emerged as a novel therapy for cancer. To identify rational candidates for anti-PD-1/PD-L1 immunotherapy in gastric cancer (GC), the abundance of PD-L1 expression was evaluated on a kind of biomarker-based molecular classification for shaping prognosis a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2019-07, p.6397
Main Authors: Sun, Yeqi, Yu, Wenwei, Guan, Wenbin, Cai, Lei, Qiao, Meng, Zheng, Leizhen, Jiang, Ruiqi, Wang, Ruifen, Wang, Lifeng
Format: Article
Language:English
Subjects:
Analysis
Cancer
Cancer treatment
Epstein-Barr virus
Health aspects
Immunohistochemistry
Immunotherapy
Innovations
Medical equipment industry
Medical research
Medical schools
Messenger RNA
RNA
Stomach cancer
Tumor proteins
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Targeting the PD-1/PD-L1 pathway has emerged as a novel therapy for cancer. To identify rational candidates for anti-PD-1/PD-L1 immunotherapy in gastric cancer (GC), the abundance of PD-L1 expression was evaluated on a kind of biomarker-based molecular classification for shaping prognosis and treatment planning. Methods: One hundred and sixty-five GCs were classified into five subgroups using immunohistochemistry (IHC) and in situ hybridization (ISH) methods, based on a panel of seven markers (MLH1, PMS2, MSH2, MSH6, E-cadherin, P53, and Epstein-Barr virus mRNA). The expression of PD-L1 in GC tissues was analyzed immunohistochemically. Results: The five categories (Epstein-Barr virus positivity, microsatellite instability, aberrant E-cadherin, aberrant P53 expression, and normal P53 expression) correspond to the reported molecular subgroups for similar proportions and clinicopathologic characteristics. Survival analysis indicated that subgroups with aberrant E-cadherin expression independently predicted a worse prognosis in GC patients (HR=2.51, P=0.010). The clinical and prognostic profiles produced by this stratification in nonintestinal-type GC were distinguishable from those in intestinal-type. Although PD-L1 was not a significant prognostic factor, that more frequent presence of PD-L1-positive in microsatellite instability tumors than other subtypes (P
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S206189